Leadership

Roger Gunn, PhD

Chief Scientific Officer

Dr. Roger Gunn is an international expert on imaging for disease understanding and drug development. He has a PhD in Applied Mathematics from Warwick University and has worked across industries including academia (Imperial College London, Oxford University & McGill University), biopharma (GSK & Imanova) and government labs (MRC Cyclotron Unit).

Dr. Gunn has made significant contributions to the development of novel imaging biomarkers, quantitative algorithms and software for a wide range of imaging applications. He currently holds professorships at Imperial College London and Oxford University and has 200 publications in the field of imaging.

CONNECT

Edward J. Hogan Jr.

Chief Operating Officer

Mr. Edward Hogan oversees the Clinical Services team including Project Management, Imaging Services, Data Management and Reader Management for early and late phase clinical trials at Invicro.

Mr. Hogan has over 26 years of clinical research experience, focusing on managing and executing Phase I through Phase IV imaging trials. He brings more than 16 years of experience in managing clinical operations with extensive experience leading cross-functional teams. Mr. Hogan has progressive business experience building and managing global cross-functional teams while leading the teams to focus on delivery and customer service, ultimately driving quality and process improvements.

CONNECT

Bill Cupelo, MS

Head of Sales

Mr. Bill Cupelo is responsible for all sales operations and account relations with a focus on clinical imaging core lab, software informatics, and data science products and services as well as strategic alliances with our pharma partners. With over 10+ years experience, Mr. Cupelo brings a sponsor and science-first mindset throughout all engagements across the Invicro enterprise. From 2010 to 2016, Bill was a Software Product Manager where he oversaw commercial product development initiatives for Invicro’s main software platforms, VivoQuant® and IPACS®. From 2016 to 2018, Mr. Cupelo served as the Vice President of Business Development and Strategic Accounts where he implemented new initiatives to support commercial goals across the enterprise. Mr. Cupelo holds an MS in Biotechnology from Georgetown University and a BS in Chemistry from the College of the Holy Cross.

CONNECT

Denise Ferraiolo, BA

SVP, Clinical Operations

Ms. Denise Ferraiolo has twenty plus years of experience in clinical research, managing and executing early Phase I through Phase 4 trials. More specifically, Denise has more than ten years of leadership experience, with an emphasis on operational expertise. Ms. Ferraiolo has a strong background in operations and the conductance of imaging trials, with a concentration on managing global cross-functional teams in Project and Data Management, Imaging Services and Clinic Operations. Her focus is on delivery, accountability, and customer satisfaction while driving quality and process improvements.

At Invicro, Ms. Ferraiolo oversees the oversees the Clinical Services group responsible for Project Management, Imaging Services, Data Management, Reader Management and Clinic/Chemistry functions for early and late phase clinical trials.

CONNECT

Ciara Finucane, MSc

VP, Discovery & Preclinical Services

Ms. Ciara Finucane joined Invicro in January 2013 and specializes in nuclear techniques, including the evaluation of molecular targets for radionuclide-mediated diagnosis and therapy of cancer. With over 15 years of experience, Ms. Finucane specializes in preclinical SPECT and PET imaging with a focus on the design, execution and project management of nuclear imaging studies.

Ms. Finucane received her honors degree in Physiology from Trinity College Dublin and her MSc in Forensic Sciences from Kings College London. Prior to Invicro, Ms. Finucane developed cancer therapeutic and imaging agents for the Center for Molecular Imaging at Bart’s Cancer Institute at Queen Mary University of London.

CONNECT

Joseph Krueger, PhD

VP, Advanced Pathology Services

Dr. Joseph Krueger serves as the Vice President of Advanced Pathology Services at Invicro. In his role, Dr. Krueger is responsible for developing new biomarker applications to meet drug development needs, and provides scientific expertise needed to support sponsor-based projects across therapeutic areas. Prior to joining Invicro, Dr. Krueger was Chief Scientific Officer at Flagship Biosciences, Inc., where he led the R&D and Scientific efforts in applying novel quantitative tissue image analysis approaches to immuno-oncology and rare diseases to support drug and companion diagnostic development. Prior to Flagship Biosciences, he served in senior scientific roles in oncology drug development for OSI Pharmaceuticals in Boulder, CO and Pfizer in Andover, MA. Dr. Krueger completed his postdoctoral fellowship at the Scripps Research Institute and the University of California, San Diego after completing his PhD in Cancer Biology at Wayne State University in Detroit, MI.

CONNECT

Benjamin Murphy, CPA

VP, Finance

Mr. Ben Murphy joined Invicro in 2017 and has previously served as Invicro’s Financial Controller.

Mr. Murphy has over 10 years of experience specializing in Pharma, Biotech and CRO businesses under public and private reporting environments. At Invicro, Mr. Murphy leads the Accounting and Finance functions including treasury, financial controls, budgeting and financial reporting. He is a Certified Public Accountant in the state of Massachusetts and an active member of the AICPA. Mr. Murphy received his B.S. Degree in Accounting from the University of Connecticut School of Business.

CONNECT

Jan Passchier, PhD

EVP, Global Head of Laboratories & Clinics

Dr. Jan Passchier is a radiochemistry expert who specializes in imaging and drug development. He holds a PhD in PET radiochemistry from Groningen University. Dr. Passchier started his career at GlaxoSmithKline where he identified and developed novel tool compounds for a large variety of CNS, metabolic and respiratory indications.

Dr. Passchier played a significant role in the design and realization of the GlaxoSmithKline Clinical Imaging Centre where he headed the chemistry group. Following a spin-out of the center to Imanova Ltd, now part of Invicro, his role expanded to include operational responsibility for the business. Dr. Passchier has a keen interest and deep understanding of the application of molecular imaging to disease understanding and drug development.

CONNECT

Eugenii (Ilan) Rabiner, MD

EVP, Head of Translational Applications

Dr. Ilan Rabiner is a psychiatrist and psychopharmacologist who was part of the team that set up the GlaxoSmithKline Clinical Imaging Centre, which transitioned to become Imanova in Sep 2011. Dr. Rabiner spent 10 years at GlaxoSmithKline, and was head of Clinical Imaging Applications at the Translational Medicine and Technologies group.

Dr. Rabiner received a BSc in Physiology and Medical Biochemistry and a MBBCh, from the University of the Witwatersrand, and specialist training in psychiatry at the University of Cape Town. He was trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London.

Dr. Rabiner’s research interests focus on the application of molecular imaging to human pathophysiology, psychopharmacology and central nervous system drug development. He is an author of >140 peer reviewed publications.

CONNECT

Fiona Roberts

VP, Site Operations UK

Ms. Fiona Roberts has over 24 years of experience in the molecular imaging field, and provides site leadership and oversight of all operational activities at the Invicro facility in London.

She joined Invicro London (formerly Imanova) in 2015 as Clinical Operations Manager overseeing the delivery of imaging studies in support of clinical research. Prior to Invicro, Ms. Roberts held key commercial clinical operations roles at Alliance Medical and HCA International in London. Previously, she held instrumental roles at Austin Health in Melbourne, Australia and Guy’s and St Thomas NHS Trust London, where she gained her clinical SPECT and PET imaging experience.

Ms. Roberts holds a Bachelor of Applied Science in Medical Radiations from the Royal Melbourne Institute of Technology. 

Piran Sucindran

VP, Global Head of Quality and Regulatory

Mr. Piran Sucindran leads the global quality and regulatory organization at Invicro, with teams overseeing Quality Systems, Third Party QA Oversight, Chemistry QA, Systems Compliance, and Regulatory Affairs.

Mr. Sucindran has over 15 years’ experience working in clinical research, specializing in Good Clinical Practice and Good Manufacturing Practice. Mr. Sucindran has experience working both in the UK National Health Service and the commercial sector. He is a member of the Research Quality Association GCP Committee, has completed an MSc in Quality Management in Scientific Research and Development and BSc in Molecular Medicine.

CONNECT

Phillip Kuo, MD, PhD

Distinguished Scientist

Dr. Kuo is board-certified in Internal Medicine and Radiology with a special certification in Nuclear Medicine and was Chief of Nuclear Medicine for a university medical center for 10 years. Dr. Kuo has more than 100 publications and has served as principal investigator and co-principal investigator on multiple NIH grants and investigator-initiated trials.  

Dr. Kuo’s experience includes design and supervision of phase I-III clinical trials including theranostics with PET, SPECT, MRI, and radiotherapeutics. Dr. Kuo’s experience also includes participation in USFDA and EMA meetings for regulatory approval. As a reader for clinical trials, he has reviewed over ten thousand scans for oncology or neurology. 

Kenneth Marek, MD

Distinguished Scientist

Ken is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers for these disorders for PD, AD, HD and other disorders. He has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials including PPMI and PARS.

John Seibyl, MD

Distinguished Scientist

John is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. John is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Kenneth Marek, he has directed and continues to direct several international multicenter imaging studies. John is an author on over hundred publications on CNS imaging.

CONNECT